Professor Arnold Caplan from Case Western Reserve with Dr. Riordan and friends during his recent trip to Panama. Dr. Caplan is known as the “Father of the Mesenchymal Stem Cell” although these days, he prefers the term “Medicinal Signaling Cells”.
A study published in the Jul-Dec 2014 edition of the Journal of Natural Science, Biology and Medicine entitled “Bone marrow injection: A novel treatment for tennis elbow“ concludes that a single injection of bone marrow aspirate concentrate (BMAC) into the elbow lead to significant improvement of patients suffering from tennis elbow.
The study followed 30 patients for 12 weeks and concluded that treatment of tennis elbow patients with single injection of BMA showed a significant improvement in short to medium term follow-up.
Perhaps more importantly, it concluded that, “In future, such growth factors and/or stem cells based injection therapy can be developed as an alternative conservative treatment for patients of tennis elbow, especially who have failed non-operative treatment before surgical intervention is taken.”
Fast forward to the present where at RMI, we are augmenting BMAC with *AlphaGEMS, a proprietary, pliable tissue allograft (transplant) derived from human placental amnion, which functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. AlphaGEMS contains 108 different growth factors including WNT-4 and prostaglandin.
Prostaglandin inhibits inflammation, which occurs after injury and marks the beginning of the healing process. The faster we can tame this inflammation, the sooner the body can move on to the next phase of healing, regeneration. It’s important to note that AlphaGEMS has more than 60 times the amount of prostaglandin compared to other products.
WNT4 is arguably the single most important molecule required for wound healing. AlphaGEMS has more than 10 times the amount of WNT4 as competing products.
For more information about BMAC and AlphaGEMS at the Riordan-McKenna Institute Click Here.
If you are suffering from tennis elbow and would like to be evaluated for treatment, please start by completing our online medical history. Once we receive it, our staff will contact you to answer general questions and guide you through the rest of the application process, which usually includes a in-office evaluation with Dr. McKenna for local patients or a free telephone consultation for those who live further away.
About Tennis Elbow
Tennis elbow is an inflammation of the tendons that join the forearm muscles on the outside of the elbow. The forearm muscles and tendons become damaged from overuse — repeating the same motions again and again. This leads to pain and tenderness on the outside of the elbow. More on Tennis Elbow from AAOS.
About: Bone marrow injection: A novel treatment for tennis elbow
The objective of this prospective study was assessment of efficacy of bone marrow aspirate (BMA) (containing plasma rich in growth factors and mesenchymal stem cells) injection in treatment of tennis elbow.
Materials and Methods:
A total of 30 adult patients of previously untreated tennis elbow were administered single injection of BMA. This concentrate was made by centrifugation of iliac BMA at 2000 rpm for 20-30 min and only upper layer containing platelet rich plasma and mononuclear cells was injected. Assessment was performed at baseline, 2 weeks, 6 weeks and 12 weeks using Patient-rated Tennis Elbow Evaluation (PRTEE) score.
Baseline pre-injection mean PRTEE score was 72.8 ± 6.97 which decreased to a mean PRTEE score of 40.93 ± 5.94 after 2 weeks of injection which was highly significant (P < 0.0001). The mean PRTEE score at 6 week and 12 week follow-up was 24.46 ± 4.58 and 14.86 ± 3.48 respectively showing a highly significant decrease from baseline scores (P < 0.0001). Conclusion:
Treatment of tennis elbow patients with single injection of BMA showed a significant improvement in short to medium term follow-up. In future, such growth factors and/or stem cells based injection therapy can be developed as an alternative conservative treatment for patients of tennis elbow, especially who have failed non-operative treatment before surgical intervention is taken.
*Tissue used for AlphaGEMS is donated after normal, healthy births. Once it has been fully tested for infectious diseases, sterility and a few other things, the tissue is processed by using proprietary methods developed by Neil Riordan, PhD.
Lately, especially on our Facebook Page many people are asking us, “What is the source of the stem cells?”
At the Stem Cell Institute, we use two types of stem cells. Primarily, we use allogeneic mesenchymal stem cells harvested from human umbilical cord tissue. In addition to allogeneic mesenchymal stem cells, our spinal cord injury protocol uses autologous (patient’s own) stem cells harvested from bone marrow.
Umbilical cord tissue is donated by mothers after normal, healthy births.
All donating mothers are tested for infectious diseases and have their medical histories screened. We obtain proper consent from each family prior to umbilical cord donation.
All mesenchymal stem cells harvested from umbilical cords are screened for infectious diseases to International Blood Bank Standards before they are approved for use in treatments.
A small number of umbilical cords (about 1 in 10) pass our rigorous screening process.
Dr. Riordan on the Umbilical Cord Selection Process at Stem Cell Institute
“Through retrospective analysis of our cases, we’ve identified proteins and genes that allow us to screen several hundred umbilical cord donations to find the ones that we know are most effective. We only use these cells and we call them ‘golden cells’.
We go through a very high throughput screening process to find cells that we know have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration.”
What are the advantages of treating with allogeneic human umbilical cord tissue (HUCT)-derived mesenchymal stem cells?
- Anyone can be treated since HUCT mesenchymal stem cells are immune system privileged. Human Leukocyte Antigen (HLA) matching is not necessary.
- The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
- Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
- Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
- No need to collect stem cells through invasive procedures such as liposuction or bone marrow collection
- There is a growing body of evidence showing that mesenchymal stem cells from umbilical cords are more robust than mesenchymal stem cells from other sources such as fat.
The body’s immune system is unable to recognize human umbilical cord tissue (HUCT)-derived mesenchmyal stem cells as foreign and therefore they are not rejected. HUCT stem cells have been administered thousands of times at the Stem Cell Institute and there has never been a single instance rejection (graft vs. host disease). Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat and therefore, they are considered to be more “potent”.
“Thank you everyone for your kind words. Stem cells did not cure my MS, but they have improved my quality of life so much it is unbelievable. I have always had the support of my family and friends, and for this, I have been VERY appreciative. Stem cell therapy has given me a new quality of life and I thank God, my family and Dr. Neil Riordan at the Stem Cell Institute in Panama City, Panama. Life is good :-)” – Cathy Miller Duke
“Last year on this day, my mom wasn’t able to participate in the Mackinac Bridge walk because, at exactly this time, she was in Panama receiving stem cell therapy, hoping it would improve her quality of life. Today, she was able to participate and walk that bridge…without a cane. (And apparently, she walked backwards a little jogged some too!) So proud of you mom!” – Michelle Duke Thompson
PRESS RELEASE – Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound
Dallas-Fort Worth (PRWEB) August 28, 2015 – Riordan-McKenna Institute founders, stem cell expert Neil Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies in Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound.
The case involved a 78-year-old male, who presented with a non-healing surgical wound following a right total knee replacement performed six weeks prior. The patient had not responded after 6 weeks of conservative wound care and the wound showed no signs of healing.
Dr. McKenna irrigated the wound in the operating room under pulse lavage and then placed two AlphaPATCH dry amniotic membranes (4 cm x 4 cm) over the wound before dressing it.
At the two-week follow-up visit, a central scab had formed. At four-weeks, the wound had completely scabbed over. At eight-weeks the scab had just fallen off and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.
The case report, entitled “Case Report Of Non-Healing Surgical Wound Treated With Dehydrated Amniotic Membrane” is published in the July issue of the Journal of Translational Medicine. Authors include Dr. Riordan, Dr. McKenna, Troy Chandler, PA-C, and Ben George, PA-C. This milestone in Dr. Riordan and Dr. McKenna’s ongoing study of biologic wound healing using amniotic tissue products and stem cells is the third peer reviewed journal article on regenerative medicine published by the Riordan McKenna Institute.
A common misconception is that dehydrated amniotic membrane products like AlphaPATCH contain live stem cells. Although dehydrated amniotic membrane does not contain any stem cells, it does contain a number of growth factors that promote healing and stimulate the body’s own stem cells to become activated and likely behave more similar to stem cells in a younger person.
“It’s gratifying to have this new tool in my toolbox. I treated conservatively and was getting nowhere. Even in a patient with a significant smoking history and decreased blood flow to his legs, we were able to achieve this result. Chronic wounds can be very frustrating for both the patient and the caregiver,” remarked Troy Chandler, PA-C, who participated in the patient’s treatment.
About Riordan-McKenna Institute (RMI)
RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.
RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.
*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/
801 E. Southlake Blvd.
Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154
About Amniotic Therapies
Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.
11496 Luna Rd. Suite 800
Tel: (972) 465-0496
Ryan Benton is the first patient in the United States to receive human umbilical cord-derived mesenchymal stem cell therapy for Duchenne’s muscular dystrophy. The US FDA granted Ryan this trial under compassionate use. Ryan first began treatments at the Stem Cell Institute in Panama before being able to receive treatments in his hometown of Wichita, Kansas.
Clinical Trials for Multiple Sclerosis and Rheumatoid Arthritis using Umbilical Cord Tissue Mesenchymal Stem Cells
Stem Cell Institute and Medistem Panama founder, Neil Riordan, PhD discusses clinical trials for multiple sclerosis and rheumatoid arthritis using umbilical cord tissue-derived mesenchymal stem cells at our fall stem cell seminar in San Antonio.
For more information about these trials and others, please visit www.translationalbiosciences.com. The multiple sclerosis trial is full but the RA trial is still recruiting as of November 24, 2014.
How do we select umbilical cords for use? Medistem has identified proteins and genes in the cells that allow us to screen hundreds of umbilical cords to select only the ones containing the specific types of cells that have the best anti-inflammatory properties, the best immune modulating capacity and the best ability to stimulate regeneration.
How therapy using umbilical cord tissue-derived mesenchymal stem cells (MSCs) differs from bone marrow transplants used in cancer patients.
Properties of umbilical cord MSCs:
- Modulate the immune system
- Increase the number of T-regulatory cells
- Block clonal expansion of activated T cells
- MSCs in patients with autoimmune diseases don’t work properly
How demyelination occurs in MS patients and how MSCs act on the immune system to slow it down or stop it.
Treated MS patient follow-up survey results at 120 days and 1 year after treatment.
Television news story about Sam Harrell’s return to coaching football after severe MS symptoms forced him into early retirement.
Results from a 172 patient study on treating rheumatoid arthritis with intravenous umbilical cord tissue mesenchymal stem cells in which all patients improved.
These trials may be viewed on the National Institutes of Health web site www.clinicaltrials.gov
Those interested in stem cell therapy for MS may still apply for private treatment on this site.
After FDA Approval, Duchenne’s Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the United States
Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday at Asthma and Allergy Specialists of Wichita, KS following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.
Wichita, KS (PRWEB) September 10, 2014Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.
Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.
This trial, officially entitled “Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD)” marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchenne’s in the United States.
Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.
This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.
The stem cell technology being utilized in this trial was developed by renowned stem cell scientist Neil H. Riordan, PhD. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for their US-based cGMP laboratory partner.
Funding for this trial is being provided by the Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for alternative therapies to people like Ryan.
About Van Strickland, MD
Dr. Strickland came to Wichita in 1979 from his fellowship at the National Jewish Hospital in Denver. Since then he has spent one year in Wyoming, one year in Dallas, Texas and one year in Lee’s Summit Missouri before returning to full-time practice in Wichita, Kansas.
Dr. Strickland has been a clinical faculty member at The University of Kansas School of Medicine in Wichita in the department of Pediatrics and later in the department of internal medicine for most of his years in Wichita.
Dr. Strickland is certified by the American Board of Allergy and Immunology and the American Board of Pediatrics. He graduated from Baylor College of Medicine in Houston, Texas and served a full residency in Pediatrics at Baylor and a fellowship in Allergy and Immunology in Denver at National Jewish. He has trained in allergy and immunology at the University of Texas School of Medicine in Galveston as an elective while at Baylor and was a student on the team with Mary Ann South, MD and John Montgomery, MD who put baby David in the Bubble (Bubble Boy).
Dr. Strickland is a fellow of The American Academy of Allergy, Asthma and Immunology, The American College of Allergy, Asthma and Immunology, The American Association of Certified Allergists, The American Academy of Pediatrics, and The American College of Physicians. Dr Strickland has been recognized in the “Top Doctors in Wichita” listing several times.
Allergy & Asthma Consultants
MHV Strickland M.D.
10021 W. 21st St. Wichita, KS 67205
Phone: +1 (316) 722-4800
Toll-free: +1 (800) 347-4800
Fax: +1 (316) 722-5117
Web Site: http://www.stricklandallergy.com
About Neil Riordan, PhD
Neil Riordan PhD is the co-founder of the Riordan-McKenna Institute, a regenerative orthopedics clinic that will open its doors in Southlake, Texas in late 2014. RMI will offer non-surgical stem cell treatments and stem cell enhanced surgeries for orthopedic conditions. He is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI’s stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).
Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting seven IRB-approved clinical trials in Panama for autism, multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, and cerebral palsy are scheduled to commence in late 2014 upon IRB approval.
Dr. Riordan’s research team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.
Dr. Riordan has published over 60 scientific articles in international peer-reviewed journals and authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. He is listed on more the 25 patent families, including 11 issued patents including a 2010 patent for a new cellular cancer vaccine.
In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central.
Neil Riordan, PhD
801 E. Southlake Bivd.
Southlake, TX 76092
Phone: +1 (817) 776-8155
Fax: +1 (817) 776-8154
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014
New York, NY (PRWEB) April 09, 2014
The Stem Cell Institute, located in Panama City, Panama, will present an informational umbilical cord stem cell therapy seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.
Neil Riordan PhD – “Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury”
Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.
Jorge Paz-Rodriguez MD – “Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus”
Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.
Light snacks will be served afterwards. Our speakers and stem cell therapy patients will also be on hand to share their personal experiences and answer questions.
Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-tickets-11115112601 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.
About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.
In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.
To-date, SCI has treated over 2000 patients.
For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama
About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.
Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama
Phone: +507 306-2601
Fax: +507 306-2601
About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.
Translational Biosciences webSite: http://www.translationalbiosciences.com
Stem Cell Pioneers featured Dr. Riordan in its February installment of “Ask the Doctor”, a monthly segment that features stem cell scientists and doctors answering questions from readers about stem cell therapy.
Over the next several days, we will share these questions and Dr. Riordan’s answers with our readers.
Question: Are there some conditions such as neurological ones that respond better when the cells are greatly expanded? Is a high quantity essential for success or is that something that may be more of a selling point at some clinics? I have also seen this advertised for COPD and other conditions. It’s almost like the more cells the better, but I would like your opinion.
Dr. Riordan’s Answer: That really depends on the quality of the cells after expansion. If they are still robust, not senescent, and still have a good secretion profile, then the more the better may be useful up to a point. If you take a small pool of starter cells and expand them to exhaustion, then I don’t think you are going to have a very good product. The MSCs used in Panama are not expanded beyond passage 5—a point at which there is no senescence in the population and they have a robust cytokine secretion profile. In order to use only cells that meet our release criteria, cells from approximately one (1.2 to be exact) out of 10 donated umbilical cords are used.
Contrast that to cells from a patient’s own fat tissue that are expanded. Firstly, the starting cells may, and many times are not very robust—they secrete little or no beneficial cytokines or chemokines, and must be expanded to hilt in order to hit the cell number. Please see my answer to number 7 for more on this subject.
This brings up a slightly different, yet related topic. There has been a lot of talk at recent meetings about more defined endpoints for the cells being used, and I couldn’t agree more. There are MSCs from bone marrow, menstrual blood, fat tissue, umbilical cord (even different parts of the umbilical cord—around the blood vessels, from the Wharton’s jelly, from the subepithelium, from the cord blood itself—which are most likely contaminants from a bruised placenta rather than the blood), teeth, amniotic membrane, amniotic fluid just to name sources in the “we didn’t mess with mother nature” adult stem cell world. Add to that the infinite variables when you consider the age and physical condition of the donor, particularly when using adipose or bone marrow as a source material and we, as a field, could be saying almost anything by using the term, “mesenchymal stem cell.” I think it is time that there is standardization in the field beyond the current definition of expressing/not expressing certain surface markers and the ability to differentiate into fat, bone, and cartilage. That standardization could come from using endpoints such as “remaining proliferative capacity (the number of doublings achievable in culture from the treatment cell bank), the secretome, even if there is standardization of one or two molecules, such as HGF, or one of the prostaglandins.
In the future I believe the field will take it a step further by measuring, even by a surrogate marker, the potential effects of the cells on the target condition. In the case of autoimmunity the cells and their secretions could be tested for their capacity to modulate the immune system. In the case of inflammatory conditions, the cells and their secretions could be tested for the ability to control or block inflammation.